Politics and Legality
Lucid News
2023-11-02
An Ambitious Vision Drives Kentucky’s Ibogaine Plan to Treat Opioid Dependency
A Kentucky commission will soon vote on whether to commit $42 million toward a psychedelic-assisted therapy moonshot that could transform treatment for opioid use disorder nationally.
Share:
Related News
Live and Awake in LA
Having attended the surprisingly few SoCal events over the past few years, it was such a welcome pleasure to see familiar faces coming together in LA for 3 days of meaningful conversations centered around healing, community, access, learning, and networking at Psychedelic Awakening 2025 hosted by Psychedelic Institute of Los Angeles.
Read More
DEA Calls For Increased Production Of Some Psychedelics For Research, As Marijuana Quotas Level Out Ahead Of Scheduling Decision
The Drug Enforcement Administration (DEA) has released new quotas for the production of Schedule I and Schedule II controlled substances for research purposes—calling for an increase in the manufacturing of the psychedelics ibogaine, psilocybin and psilocyn, while continuing to maintain stable quotas for other substances such as marijuana, THC and MDMA. As DEA prepares to […]
Read More
Analysis: FDA Advisory Committee Snubs MDMA-Assisted Therapy for PTSD in Overwhelming “No” Vote
Following last week’s negative headlines, we review how Lykos Therapeutics unsuccessfully sought to reassure the committee, how its apparent policy of minimal engagement might have backfired…
Read More
Bipartisan Congressional Lawmakers Tell VA To Prepare Plan For MDMA-Assisted Therapy As FDA Considers Approving The Psychedelic
Bipartisan congressional lawmakers are asking the U.S. Department of Veterans Affairs (VA) to produce a plan to begin providing MDMA-assisted therapy for veterans as soon as the psychedelic is approved by the Food and Drug Administration (FDA). In a letter sent to VA Under Secretary Shereef Elnahal on Tuesday, Reps. Morgan McGarvey (D-KY), Morgan Luttrell […]
Read More